PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Bannon’s War Room | Evening Edition | Recorded May 12, 2021 | Video: 48 Minutes 58 Seconds

Show Me

NBC News: Election Security Experts Say U.S. Voting Systems Do Connect To The Internet & Warn Serious Vulnerability That Can Affect Future Elections

Show Me

We Were Lied To Again | Voting Machines Are Connected To The Internet | NBC News

Show Me

Easy to Vote, Hard to Cheat: An Election Integrity Approach all Americans can Support

Show Me

Senator Marsha Blackburn Calls for New Cybersecurity Measures

Show Me

BREAKING: Trump Backs UK Government’s New Voter ID Requirement

Show Me

Mainstream Media Warned Us About Voting Machines, But Then Rebuked Their Own Findings For Political Reasons | NBC Investigative Report | Video: 2 Minutes 51 Seconds

Show Me

‘Corrupt Republicans’: Maricopa County Supervisors Never Had Access to Running Their Own Election | 3 Minutes 30 Seconds

Show Me

Virginia, Florida Governors Declare States of Emergency Over Colonial Pipeline Hack

Show Me

Japan Passes Digital Law As Virus Underscores Tech Struggles

Show Me

NTD News Banned By Youtube & Vimeo For Broadcasting A United States Senate Hearing – December 16, 2020 Broadcast | Video: 50 Minutes 17 Seconds

Show Me

Sidney Powell admits it was all a lie

Show Me

May 11, 2021 | Nightly News Rebroadcast | Video: 50 Minutes 40 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 11, 2021 | Video: 48 Minutes 25 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 11, 2021 | Video: 48 Minutes 29 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded May 11, 2021 | Video: 48 Minutes 58 Seconds

Show Me

Bill Gates Tells Another Big Lie About Vaccine Production

Show Me

From The Desk Of Donald J. Trump

Show Me

Arizona Governor Signs Law Designating Gun Stores as Essential Firms

Show Me

Sen. Grassley: Biden officials withheld info on national security risks posed by border crisis

Show Me

GOP Chair Dr. Kelli Ward: Election Should Not Have Been Certified If Maricopa County Election Routers Were Shared with Law Enforcement

Show Me

Facts Matter (May 10): Arizona Senate Tells Maricopa Officials to Turn Over Routers or Face Subpoenas

Show Me

The Far Right Is Ready to Claim a Slice of Real Power in Sweden

Show Me

FCC Commissioner Slams Top Baltimore Prosecutor’s ‘Chilling’ Request for Investigation Into Fox-Affiliate Over Bias, Tucker Carlson Show

Show Me

Pentagon’s new anti-extremism chief supports radical leftist views, critics charge

Show Me

Italian woman mistakenly given SIX doses of the Pfizer vaccine in one go

Show Me

Adjusted Model Estimates 40 Percent More COVID Deaths

Show Me

This Is What Democrats Call Peaceful Protests | Veteran Beaten and Hospitalized in Portland, Oregon | Video: 2 Minutes 47 Seconds

Show Me

Casual sex WILL be allowed from May 17 after Government gives green light for people to meet inside

Show Me

Vatican warns US bishops over get-tough Communion proposals

Show Me

NASA criticizes China over handling of rocket re-entry after debris crashes in Indian Ocean

Show Me

FBI names pipeline cyberattackers as company promises return

Show Me

Biden HHS Rolls Back Religious Conscience Protections for Doctors

Show Me

Elise Stefanik: ‘Running for Chair Because We Need a Unified GOP Leadership Team’

Show Me

Biden’s Latest Jobs Whopper

Show Me

FDA Authorizes Pfizer-BioNTech Vaccine for Children 12 to 15

Show Me

May 10, 2021 | Nightly News Rebroadcast | Video: 51 Minutes

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 10, 2021 | Video: 48 Minutes 48 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 10, 2021 | Video: 48 Minutes 24 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded May 10, 2021 | Video: 48 Minutes 24 Seconds

Show Me